LEXINGTON, Massachusetts & SYDNEY, Australia – 9 October 2013 – GI Dynamics, Inc. (ASX: GID) announced today that Stuart A. Randle, president and chief executive officer, was invited to participate in the Cleveland Clinic’s 11th Annual Medical Innovation Summit, “Finding Balance through Innovation: Obesity, Diabetes & the Metabolic Crisis,” being held Oct. 14-16, 2013, at the Cleveland Convention Center in Cleveland, Ohio. Mr. Randle will participate in the panel titled “Understanding and Treating Diabetes”, which will feature experts from industry and academia discussing the costs and burdens of type 2 diabetes, as well as the latest treatments being used to manage this disease. The panel will take place Wednesday, Oct. 16 at 8:35 a.m. ET.

Cleveland Clinic’s annual Medical Innovation Summit is one of the premier healthcare gatherings in the U.S., convening approximately 1,100 top CEO’s, venture capitalists, investors and healthcare leaders for a candid exchange on new medical technology, its future, recent breakthroughs and continuing challenges. For more information, please visit www.clevelandclinic.org/innovations

About GI Dynamics

GI Dynamics, Inc. (ASX: GID) is the developer and marketer of EndoBarrier®, a breakthrough device that represents an entirely new class of non-surgical, non-pharmaceutical therapy for the treatment of type 2 diabetes and/or obesity. EndoBarrier is approved and commercially available in multiple countries outside the U.S. EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States.  GI Dynamics is conducting a pivotal clinical trial of EndoBarrier in the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are obese. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts. For more information, please visit www.gidynamics.com. 

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our EndoBarrier® including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrollment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. GI Dynamics does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. GI Dynamics may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, described in “Risk Factors” in our Prospectus lodged with the Australian Securities & Investments Commission on 3 August 2011.

Investor Enquiries: Media Enquiries:
United States

Robert Crane, Chief Financial Officer

+1 (781) 357-3250

 

United States/Europe:

Dan Budwick, Pure Communications Inc.

+1 (973) 271-6085

Australia

David Allen or John Granger, Hawkesbury Partners Pty Limited

+61 2 9325 9046

Australia:

Haley Price, Buchan Consulting Group

+61 3 8866 1215